Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

March 23, 2016

Primary Completion Date

April 14, 2017

Study Completion Date

April 14, 2017

Conditions
Tourette Syndrome
Interventions
DRUG

NBI-98854

DRUG

Placebo

Trial Locations (44)

Unknown

Sun City

Springdale

Long Beach

San Bernardino

San Diego

Upland

Bradenton

Gainesville

Hialeah

Loxahatchee Groves

Melbourne

Orlando

St. Petersburg

Tampa

Atlanta

Chicago

Naperville

Wichita

Boston

Natick

Ann Arbor

Bloomfield Hills

Lincoln

Nashua

Marlton

Summit

Manhasset

New York

Rochester

Cincinnati

Middleburg Heights

Oklahoma City

Franklin

Nashville

Dallas

DeSoto

Fort Worth

Houston

Irving

Orem

Salt Lake City

Kirkland

Seattle

Spokane

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY